CN115335071A - 用于治疗雷特综合征的方法和组合物 - Google Patents

用于治疗雷特综合征的方法和组合物 Download PDF

Info

Publication number
CN115335071A
CN115335071A CN202080090500.2A CN202080090500A CN115335071A CN 115335071 A CN115335071 A CN 115335071A CN 202080090500 A CN202080090500 A CN 202080090500A CN 115335071 A CN115335071 A CN 115335071A
Authority
CN
China
Prior art keywords
subject
trefenatide
administered
rett syndrome
weighs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080090500.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·达维斯
J·M·尤阿卡姆
L·I·格拉斯
N·E·琼斯
S·P·奥斯特霍特
O·D·帕斯瓜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noren Pharmaceutical Co ltd
Acadia Pharmaceuticals Inc
Original Assignee
Noren Pharmaceutical Co ltd
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noren Pharmaceutical Co ltd, Acadia Pharmaceuticals Inc filed Critical Noren Pharmaceutical Co ltd
Publication of CN115335071A publication Critical patent/CN115335071A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Peptides Or Proteins (AREA)
CN202080090500.2A 2019-10-28 2020-10-28 用于治疗雷特综合征的方法和组合物 Pending CN115335071A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962927008P 2019-10-28 2019-10-28
US62/927,008 2019-10-28
US202063031201P 2020-05-28 2020-05-28
US63/031,201 2020-05-28
PCT/US2020/057627 WO2021086892A1 (en) 2019-10-28 2020-10-28 Methods and compositions for treatment of rett syndrome

Publications (1)

Publication Number Publication Date
CN115335071A true CN115335071A (zh) 2022-11-11

Family

ID=75715568

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080090500.2A Pending CN115335071A (zh) 2019-10-28 2020-10-28 用于治疗雷特综合征的方法和组合物

Country Status (14)

Country Link
US (1) US20220339138A1 (https=)
EP (1) EP4051308A4 (https=)
JP (2) JP2022553888A (https=)
KR (1) KR20220106982A (https=)
CN (1) CN115335071A (https=)
AU (1) AU2020376801A1 (https=)
BR (1) BR112022008095A2 (https=)
CA (1) CA3156680A1 (https=)
CL (1) CL2022001079A1 (https=)
CO (1) CO2022007501A2 (https=)
IL (1) IL292617B2 (https=)
MX (1) MX2022004785A (https=)
TW (1) TW202116300A (https=)
WO (1) WO2021086892A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310045A (en) 2021-07-12 2024-03-01 Acadia Pharm Inc Crystalline forms of tropintide
WO2023242844A1 (en) * 2022-06-15 2023-12-21 Ramot At Tel-Aviv University Ltd. Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis
WO2025262646A1 (en) * 2024-06-22 2025-12-26 Biophore India Pharmaceuticals Pvt. Ltd Dosage forms of trofinetide and its pharmaceutically acceptable salt thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709817B1 (en) * 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
US20140147491A1 (en) * 2011-01-27 2014-05-29 Larry Glass Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
US20180140601A1 (en) * 2013-07-25 2018-05-24 Neuren Pharmaceuticals Limited Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130691A2 (en) * 2013-02-20 2014-08-28 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
GB2554064B (en) * 2016-09-01 2019-11-20 Jit Singh Shailinder An enteral feeding tube

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709817B1 (en) * 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
US20140147491A1 (en) * 2011-01-27 2014-05-29 Larry Glass Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
US20180140601A1 (en) * 2013-07-25 2018-05-24 Neuren Pharmaceuticals Limited Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIEL G GLAZE等: "A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome", PEDIATRIC NEUROLOGY, vol. 76, 8 July 2017 (2017-07-08), pages 37 - 46, XP085258084, DOI: 10.1016/j.pediatrneurol.2017.07.002 *
DANIEL G GLAZE等: "Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome", NEUROLOGY, vol. 92, no. 16, 16 April 2019 (2019-04-16), pages 1912, XP055932138, DOI: 10.1212/WNL.0000000000007316 *

Also Published As

Publication number Publication date
TW202116300A (zh) 2021-05-01
CA3156680A1 (en) 2021-05-06
CL2022001079A1 (es) 2023-04-21
EP4051308A4 (en) 2023-08-23
MX2022004785A (es) 2022-05-16
CO2022007501A2 (es) 2022-08-30
KR20220106982A (ko) 2022-08-01
US20220339138A1 (en) 2022-10-27
AU2020376801A1 (en) 2022-06-09
IL292617B1 (en) 2025-11-01
IL292617B2 (en) 2026-03-01
EP4051308A1 (en) 2022-09-07
WO2021086892A1 (en) 2021-05-06
BR112022008095A2 (pt) 2022-07-12
IL292617A (en) 2022-07-01
JP2025148461A (ja) 2025-10-07
JP2022553888A (ja) 2022-12-26

Similar Documents

Publication Publication Date Title
JP2025036702A (ja) 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
US20220339138A1 (en) Methods and compositions for treatment of rett syndrome
ES2726223T3 (es) Composiciones que comprenden ketamina para el tratamiento de un trastorno del espectro autista
CN112423789A (zh) 用于治疗抑郁症的艾司氯胺酮
KR20210104084A (ko) 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
US12138254B2 (en) Chronic nightly dosing of lasmiditan for migraine prevention
KR20250005175A (ko) 양극성 장애의 치료를 위한 5-meo-dtm
CN114126595A (zh) 用于治疗抑郁症的艾司氯胺酮
TW202341995A (zh) 用於治療cns相關病症之神經活性類固醇
Hall et al. A balanced randomised placebo controlled blinded phase IIa multi-centre study to investigate the efficacy and safety of AUT00063 versus placebo in subjective tinnitus: The QUIET-1 trial
Wartna et al. Symptomatic treatment of pollen‐related allergic rhinoconjunctivitis in children: randomized controlled trial
Masand et al. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization
McNally et al. Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis
Evans et al. Efficacy and safety of the melanocortin pan-agonist PL9643 in a phase 2 study of patients with dry eye disease
Awan et al. A systematic review and meta-analysis of the safety and efficacy of 0.25% lotilaner ophthalmic solution in the treatment of Demodex blepharitis
Ferrer et al. REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders
Minden et al. Treatment of disorders of mood and affect in multiple sclerosis
EA051935B1 (ru) Способы и композиции для лечения синдрома ретта
Sadikova et al. The effect of melatonin supplement use on pubertal timing: target trial emulation in the Adolescent Brain Cognitive Development study
Babagi et al. An overview on unipolar major depression in adults diagnosis and management approach
Horlen et al. Antihistamines (H1 receptor antagonists)
Khuc et al. Protective effects of β-blockers on bone in older adults with dementia
Schulze et al. Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
Gisbert et al. REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination